Dianthus Therapeutics (DNTH) Operating Margin: 2022-2025
Historic Operating Margin for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to -10,173.74%.
- Dianthus Therapeutics' Operating Margin fell 879713.00% to -10,173.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -4,558.41%, marking a year-over-year decrease of 300445.00%. This contributed to the annual value of -1,633.74% for FY2024, which is 7093.00% up from last year.
- Dianthus Therapeutics' Operating Margin amounted to -10,173.74% in Q3 2025, which was up 43.78% from -18,096.89% recorded in Q2 2025.
- Over the past 5 years, Dianthus Therapeutics' Operating Margin peaked at -703.67% during Q3 2022, and registered a low of -18,096.89% during Q2 2025.
- Over the past 3 years, Dianthus Therapeutics' median Operating Margin value was -2,041.65% (recorded in 2024), while the average stood at -4,145.58%.
- Per our database at Business Quant, Dianthus Therapeutics' Operating Margin skyrocketed by 63,438bps in 2024 and then plummeted by 1,690,505bps in 2025.
- Dianthus Therapeutics' Operating Margin (Quarterly) stood at -910.04% in 2022, then slumped by 213,127bps to -3,041.31% in 2023, then skyrocketed by 63,438bps to -2,406.94% in 2024, then plummeted by 879,713bps to -10,173.74% in 2025.
- Its Operating Margin was -10,173.74% in Q3 2025, compared to -18,096.89% in Q2 2025 and -2,852.71% in Q1 2025.